var title_f17_36_17984="Fibroid embolization 4e";
var content_f17_36_17984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right uterine angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right uterine angiogram after uterine fibroid embolization demonstrates successful occlusion of the right uterine artery and its branches (arrow). The patient's symptoms subsided after the procedure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17984=[""].join("\n");
var outline_f17_36_17984=null;
var title_f17_36_17985="Dermatitis herpetiformis direct immunofluorescence linear";
var content_f17_36_17985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Direct immunofluorescence microscopy in dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Although granular deposits of IgA within the papillary dermis are the classic direct immunofluorescence findings in dermatitis herpetiformis, granular deposits of IgA along the basement membrane zone may also be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17985=[""].join("\n");
var outline_f17_36_17985=null;
var title_f17_36_17986="Patient information: Medicines for atrial fibrillation (The Basics)";
var content_f17_36_17986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16237\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?3/12/3276\">",
"         Medicines for treating atrial fibrillation",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/32/20994\">",
"         Patient information: Atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1939\">",
"         Patient information: Heart failure and atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/16/261\">",
"         Patient information: Atrial fibrillation (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38484\">",
"         Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Medicines for atrial fibrillation (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H551670829\">",
"      <span class=\"h1\">",
"       Why do I need medicines to treat atrial fibrillation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Having atrial fibrillation puts you at risk for a stroke and other problems. The medicines your doctor or nurse prescribes to treat atrial fibrillation can help lower the risk of these problems. They can also help reduce your symptoms. If you have atrial fibrillation, you might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel as though your heart is racing, pounding, skipping beats, or beating out of sync",
"       </li>",
"       <li>",
"        Have mild chest &ldquo;tightness,&rdquo; pain, or discomfort",
"       </li>",
"       <li>",
"        Feel lightheaded, dizzy, or like you might pass out",
"       </li>",
"       <li>",
"        Have trouble breathing, especially when you exercise",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551670844\">",
"      <span class=\"h1\">",
"       Which medicines might I need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are 3 main types of medicines for treating atrial fibrillation (",
"      <a class=\"graphic graphic_table graphicRef86624 \" href=\"UTD.htm?3/12/3276\">",
"       table 1",
"      </a>",
"      ). They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Heart rate control medicines",
"        </strong>",
"        &ndash; These medicines include beta blockers. They work by slowing down the speed of your heartbeat.",
"       </li>",
"       <li>",
"        <strong>",
"         Heart rhythm control medicines",
"        </strong>",
"        &ndash; These medicines include flecanide (brand name Tambocor). They work by helping the heart switch back to and stay in a normal rhythm.",
"       </li>",
"       <li>",
"        <strong>",
"         Anti-clotting medicines",
"        </strong>",
"        &ndash; These medicines make the blood less likely to clot. The oldest and most commonly used medicine",
"        <strong>",
"        </strong>",
"        is",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"         warfarin",
"        </a>",
"        (brand name: Coumadin). If you take warfarin, you&rsquo;ll need regular blood tests to monitor warfarin's effects. There are 2 newer medicines that work as well as warfarin and don&rsquo;t require blood tests. They are",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"         dabigatran",
"        </a>",
"        (brand name: Pradaxa) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?13/41/13973?source=see_link\">",
"         rivaroxaban",
"        </a>",
"        (brand name: Xarelto). These medicines cost more than warfarin. That might not be a problem if they are covered by your insurance plan. But if they are not, warfarin is still a good choice, even though it is less convenient because of the needed blood testing.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most doctors prescribe heart rate control medicines for people with atrial fibrillation. This is especially true for people who are older than 65 or who have heart failure. Other people take rhythm control medicines instead. These medicines can be a better choice for people who still have symptoms when taking rate control medicines. Many people with atrial fibrillation take anti-clotting medicines. Your doctor or nurse will decide which medicines are best for you depending on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your age",
"       </li>",
"       <li>",
"        Your symptoms and how often they occur",
"       </li>",
"       <li>",
"        Your other health problems, if you have any",
"       </li>",
"       <li>",
"        How long you have had atrial fibrillation",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, people need to try several different medicines to find one that works best for them. If your medicines cause unpleasant side effects, or if you can't afford your medicines, talk to your doctor or nurse. There are often ways to deal with these problems. The first step is to let your doctor or nurse know.",
"     </p>",
"     <p>",
"      For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp available through UpToDate. The Lexicomp hand-outs explain how to use and store your medicines. They also list possible side effects and warn you if your medicines should not be taken with certain other medicines or foods.&nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H551670876\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=see_link\">",
"       Patient information: Atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"       Patient information: Heart failure and atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       Patient information: Atrial fibrillation (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/36/17986?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16237 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17986=[""].join("\n");
var outline_f17_36_17986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551670829\">",
"      Why do I need medicines to treat atrial fibrillation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551670844\">",
"      Which medicines might I need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H551670876\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/12/3276\">",
"      Medicines for treating atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=related_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_36_17987="Tetracaine (ophthalmic): Patient drug information";
var content_f17_36_17987=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tetracaine (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/45/27347?source=see_link\">",
"     see \"Tetracaine (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/18/13603?source=see_link\">",
"     see \"Tetracaine (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12608998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Altacaine;",
"     </li>",
"     <li>",
"      Tetcaine;",
"     </li>",
"     <li>",
"      TetraVisc&trade;;",
"     </li>",
"     <li>",
"      TetraVisc&trade; FORTE",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9564877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pontocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an eye exam.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3435939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tetracaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12315 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AD134220F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17987=[""].join("\n");
var outline_f17_36_17987=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12608998\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564877\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024793\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024792\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024797\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024798\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024800\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024795\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024802\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/45/27347?source=related_link\">",
"      Tetracaine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/18/13603?source=related_link\">",
"      Tetracaine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/37/24148?source=related_link\">",
"      Tetracaine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/8/38019?source=related_link\">",
"      Tetracaine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/8/43138?source=related_link\">",
"      Tetracaine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/30/29155?source=related_link\">",
"      Tetracaine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/3/25652?source=related_link\">",
"      Tetracaine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/31/2547?source=related_link\">",
"      Tetracaine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_36_17988="Skin biopsy atrophie blanche";
var content_f17_36_17988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrophie blanche",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin biopsy in atrophie blanche showing hyalinosis of a mid-dermal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17988=[""].join("\n");
var outline_f17_36_17988=null;
var title_f17_36_17989="Paricalcitol: Patient drug information";
var content_f17_36_17989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Paricalcitol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32774?source=see_link\">",
"     see \"Paricalcitol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/33/31254?source=see_link\">",
"     see \"Paricalcitol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zemplar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zemplar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12676140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop bone disease in dialysis patients.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to paricalcitol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703610",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels or high vitamin D levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take with cholestyramine, mineral oil, or antacids or magnesium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to any type of nuts or seeds, talk with your doctor. Some products have nuts in them.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High calcium level. Signs include weakness, confusion, feeling tired, headache, upset stomach and throwing up, hard stools (constipation), or bone pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop other vitamins that have vitamin D.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11993 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17989=[""].join("\n");
var outline_f17_36_17989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206463\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206464\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12676140\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012877\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012876\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012881\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012882\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012884\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012879\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012880\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012885\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012886\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32774?source=related_link\">",
"      Paricalcitol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/33/31254?source=related_link\">",
"      Paricalcitol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_36_17990="Lateral elbow ligaments";
var content_f17_36_17990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62086%7EPEDS%2F52653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62086%7EPEDS%2F52653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral elbow ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral (radial) collateral ligamentous complex stabilizes the elbow against varus forces and maintains the orientation of the elbow bones. It is composed of the radial collateral, lateral ulnar collateral, accessory collateral, and the annular ligaments. The lateral ulnar collateral ligament is the primary lateral stabilizer of the elbow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from DeLee, JC, Drez, D (Eds). Orthopaedic sports medicine: Principles and practice, W.B. Saunders, Philadelphia 1994. Copyright &copy; 1994 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medial elbow ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The medial (ulnar) collateral ligamentous complex is composed of the anterior oblique bundle, the posterior oblique bundle, and the transverse ligament. The anterior band is responsible for medial stability of the elbow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from DeLee, JC, Drez, D (Eds). Orthopaedic sports medicine: Principles and practice, WB Saunders, Philadelphia 1994. Copyright &copy; 1994 WB Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17990=[""].join("\n");
var outline_f17_36_17990=null;
var title_f17_36_17991="Riedels thyroiditis Light";
var content_f17_36_17991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Riedel's thyroiditis: Microscopic section of thyroid parenchyma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopic section (hematoxylin and eosin, magnification x 100) of the thyroid gland from a patient with Riedel's thyroiditis demonstrates replacement of the thyroid parenchyma by dense collagenous fibrous tissue mixed with lymphocytes, plasma cells, and eosinophilis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephanie L Lee, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17991=[""].join("\n");
var outline_f17_36_17991=null;
var title_f17_36_17992="Patient survival after renal transplantation";
var content_f17_36_17992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient survival after renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/36/17992/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/36/17992/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/36/17992/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/36/17992/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/36/17992/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/36/17992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/36/17992/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/36/17992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney transplantation is the treatment of choice for selected patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/1\">",
"     1",
"    </a>",
"    ]. A successful kidney transplant improves the quality of life and reduces the mortality risk for most patients, when compared with maintenance dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Survival rates post-transplantation are similar for both hemodialysis and peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The widely perceived success of transplantation must be tempered by the realization that organ demand far exceeds organ supply [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In addition, despite significant improvements in one year graft survival, the rate of chronic graft loss after the first year remains substantial.",
"   </p>",
"   <p>",
"    The following discussion will review the data relating to patient survival in patients undergoing renal transplantation. The determinants of short-term and long-term graft survival are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTORS ASSOCIATED WITH PATIENT SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient survival after renal transplantation varies based upon the source of the allograft, patient age, and the presence and degree of severity of comorbid conditions. Other possible contributing factors include gender, race, and degree of immunosuppression. One European study evaluated the determinants of patient survival after renal transplantation among 86 living donor transplant recipients and 916 deceased donor recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/8\">",
"     8",
"    </a>",
"    ]. After the first year posttransplantation, an increased risk of death was observed among patients over the age of 40, men, deceased donor recipients, those with diabetes or hypertension, and smokers. Similar adverse outcomes with smoking, including those who have ever smoked, were noted in a second study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although transplantation confers the highest survival benefit among all the different renal replacement therapies, renal allograft recipients still have a high mortality rate compared with population controls. In the previously mentioned European study, for example, the mortality of recipients of first renal transplants was 14 times higher than the age-matched population without renal failure during the first year after transplantation, and was 4 times higher after this period [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Allograft source",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival of patients receiving an allograft from a living donor is superior to those who receive a kidney from a deceased donor, including both non-extended criteria and extended criteria donors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For recipients of a living donor kidney, patient survival rate at five years posttransplantation is 91 percent.",
"     </li>",
"     <li>",
"      For those who receive a deceased non-extended criteria donor transplant, the survival rate is 84 percent.",
"     </li>",
"     <li>",
"      For those who receive a deceased extended criteria donor transplants, the respective value is 70 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These survival rates have slightly increased over the last decade, particularly among diabetic and deceased donor transplant recipients. This is most likely the result of improved one year survival of functioning renal allografts, an enhanced ability to manage intercurrent disorders, and a lower rate of death from infections (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient and deceased donor age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients of increasing age who undergo renal transplantation have a higher mortality rate than younger recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/13\">",
"     13",
"    </a>",
"    ]. In the 2003 SRTR report on the state of transplantation, for example, the one and five year survival rates for children age 6 to 10 years who received a living donor kidney were 96 and 85 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/14\">",
"     14",
"    </a>",
"    ]. For same age children who received deceased donor kidneys, it was 95 and 77 percent, respectively.",
"   </p>",
"   <p>",
"    Although lower than in children, survival of the older adult transplant recipient is currently excellent. With present therapy, the survival at one and five years of patients older than 65 years of age is approximately 90 and 70 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/15\">",
"     15",
"    </a>",
"    ]. As a result, the older dialysis patient should not be excluded as a possible transplant recipient based upon age alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/29/43480?source=see_link\">",
"     \"Renal transplantation and the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among recipients of any age, increased survival is noted with decreased age of the deceased donor. This was reported in a review of over 50,000 renal transplant recipients from the United Network of Organ Sharing database [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/16\">",
"     16",
"    </a>",
"    ]. Among recipients greater than 55 years of age, donor age group between 0 to 17, 18 to 29, 30 to 41, 42 to 54, and greater than 55 years of age was associated with an adjusted 10 year patient survival of 48, 46, 45, 37, and 35 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of systemic disorders, particularly vascular disease, is associated with poorer long-term patient survival after renal transplantation. In a single center study, high comorbidity (as assessed by the Charlson comorbidity index) correlated with an increased risk of death in both the perioperative period (hazard ratio 3.20) and greater than three months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with disease primarily affecting the kidney, such as autosomal dominant polycystic kidney disease and glomerulonephritis, have better long-term survival than those with systemic disorders, such as hypertension and diabetes. Obesity is also associated with an increased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fifty to 60 percent of deaths among kidney transplant recipients are directly attributable to cardiovascular disease, which has a reported incidence of approximately one per 100 person years at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Death from cardiovascular disease is also the most common cause of graft loss, accounting for 30 percent of graft loss from death overall, with the greatest rates early after transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/22\">",
"     22",
"    </a>",
"    ]. However, one must keep in mind that most of the deaths attributable to cardiovascular disease is amongst those with diabetes whereas infection, malignancy, and others are more commonly the cause of death among those without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since cardiovascular disease is the leading cause of death for adult renal allograft recipients, it is important to evaluate the extent and severity of coronary disease prior to transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .) Nearly one-third of all such deaths are due to acute myocardial infarction (MI), with diabetic patients having the worst survival post-MI [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among those who require intervention for coronary artery disease after transplantation, myocardial revascularization is associated with acceptable immediate and long-term survival and similar outcomes with percutaneous and surgical techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of renal transplant recipients who underwent a first coronary revascularization procedure from 1995 to 1999, in-hospital mortality was 2.3, 4,3, 9.4, and 5.0 percent for 909 stent patients, 652 percutaneous coronary angioplasty (PTCA) patients, 288 CABG (without internal mammary grafting), and 812 CABG (with internal mammary grafting) patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/26\">",
"       26",
"      </a>",
"      ]. At two years, all-cause survival was 83, 82, 74, and 83 percent for the stent, PTCA, CABG (without internal mammary grafting), and CABG (with internal mammary grafting) groups, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with PTCA, the relative risk of death or acute myocardial infarction for stent, CABG (without internal mammary grafting), and CABG (with internal mammary grafting) was 0.90, 0.80, and 0.57 (95% CI 0.42-0.76), respectively. Thus, similar long-term survival has been reported with surgical and percutaneous techniques, with the best survival being observed with coronary artery bypass grafting with an internal mammary graft. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of nearly 3000 renal transplant recipients at one institution, survival of the 83 who required either bypass surgery or angioplasty was 89, 77, and 65 percent at one, three, and five years postprocedure, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    De novo heart failure, a common condition among patients after renal transplantation, is associated with poor survival. Based upon registry data from the United States Renal Data System, the onset of heart failure increased the risk of death (adjusted hazard ratio [AHR] 2.6, 95% CI 2.4-2.9) and death-censored graft failure (AHR 2.7, 95% CI 2.4-3.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly, the development of atrial fibrillation increases the risk of death (AHR 3.2 95% CI 2.9-3.6) and death-censored graft failure (AHR 1.9, 95% CI 1.6-2.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival of diabetic patients after renal transplantation (75 to 80 percent at five years) is lower than that reported in nondiabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, these results, due largely to extrarenal vascular disease, are still markedly better than those seen with dialysis, where the five-year patient survival rate is approximately 30 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=see_link\">",
"     \"Renal transplantation in diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overall immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of overall immunosuppression used for induction therapy, maintenance therapy, and the treatment of acute rejection episodes is a major risk factor for posttransplant infection, rather than the use of a specific immunosuppressive agent. Since infections are the leading cause of mortality in the early posttransplant period, infection and allograft dysfunction caused by rejection are closely interrelated through the use of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=see_link\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Allograft function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early kidney dysfunction has a clear adverse effect upon long-term allograft survival, a paucity of data exists concerning the relationship between graft function and patient survival. In a retrospective study of nearly 600 recipients of first deceased donor allografts, significantly increased mortality was observed in patients with a primary nonfunctioning graft (ie, a graft that never functions) compared to those with less severe graft dysfunction (45 versus 20 percent at six years) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/34\">",
"     34",
"    </a>",
"    ]. The predominant cause of death was cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=see_link\">",
"     \"Differential diagnosis of renal allograft dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient survival is high among those with persistent long-term graft function. In one survey of over 86,000 patients of whom nearly 18,500 died over a 10 year period, survival at 1, 5, and 10 years was 97, 91, and 86 percent, respectively, among those with continued renal allograft function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite decreasing early acute rejection rates, long-term allograft survival rates have changed little over time. This is due to a statistically significant trend towards increasing death-censored allograft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/36\">",
"     36",
"    </a>",
"    ]. Although the underlying reasons for this trend are unclear, this may be related to a higher proportion of acute rejection episodes that fail to recover to previous baseline function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CAUSES OF DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The particular causes of death among transplant recipients has changed over time and varies with age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/12,37\">",
"     12,37",
"    </a>",
"    ]. In a single center study, for example, cardiac disease, cancer, and stroke as causes of death increased from 9.6, 1.2, and 2.4 percent, respectively, for the period 1970 to 1979 to 30.3, 13.2, and 8.0 percent for 1990 to 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, death from cardiovascular disease is much less common among younger than older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/38\">",
"     38",
"    </a>",
"    ]. Among prevalent transplant patients from 1994 to 1996, the following were the percentage of deaths due to the most significant life-threatening disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All cardiac causes accounted for 18, 33, and 37 percent of deaths for those aged 0 to 19, 20 to 44, and 45 to 64, respectively",
"     </li>",
"     <li>",
"      Infection accounted for 25, 17, and 19 percent, respectively",
"     </li>",
"     <li>",
"      Malignancy accounted for 16, 8, and 11 percent, respectively",
"     </li>",
"     <li>",
"      Other known causes accounted for 41, 24, and 18 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SURVIVAL COMPARED WITH DIALYSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The claim of many early studies that a lower mortality is found among renal transplant recipients compared with dialysis patients has been criticized because the design of most such studies was flawed. These reports frequently failed to adequately account for the higher number",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of comorbid conditions among dialysis patients. As an example, some of the benefit associated with transplantation is related to patient selection. Those treated with dialysis are usually older (mean 57 years versus 44 years for those transplanted in one study) and more likely to have type 2 diabetes and extrarenal vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given that many dialysis patients are inappropriate candidates for renal transplantation because of severe multiorgan disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    age, the assessment of relative mortality is best performed by comparing the survival rates between patients accepted for renal transplantation who have undergone surgery with those accepted for transplantation but who have not yet received a renal allograft (waiting-list patients).",
"   </p>",
"   <p>",
"    Multiple studies using these two comparative groups have found that patient survival is clearly",
"    <strong>",
"     better",
"    </strong>",
"    with renal transplantation than with dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/2-4,40-44\">",
"     2-4,40-44",
"    </a>",
"    ]. In one of the largest, most comprehensive studies to date, survival analysis using data from the United States Renal Data System (USRDS) was performed on nearly 230,000 dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/40\">",
"     40",
"    </a>",
"    ]; among the 46,000 placed on a waiting list for transplantation, 23,000 subsequently underwent a first cadaveric transplant. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The annual death rate was significantly lower among transplant patients compared with waiting list-patients (3.8 versus",
"      <span class=\"nowrap\">",
"       6.3/100",
"      </span>",
"      patient-years).",
"     </li>",
"     <li>",
"      After the first two weeks post-transplantation, the risk of death was lower among transplant recipients compared with waiting-list patients. As an example, the mortality risk at three to four years was nearly 70 percent lower among transplant recipients (relative risk of 0.32, P&lt;0.001). Because of the initially higher risk with transplant surgery, the likelihood of survival only became equal among the two patient groups at day 244 post-transplantation.",
"     </li>",
"     <li>",
"      Improved survival with transplantation was observed among diabetics, African-Americans, and in all age groups, including those 60 to 74 years old.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar survival benefits associated with transplantation were observed in a second study of over 100,000 patients in the United States placed on the transplant waiting-list between 1988 and 1996, of whom nearly 74,000 eventually received a renal allograft [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/42\">",
"     42",
"    </a>",
"    ]. Although the relative risk for death decreased over time in both groups, the annual death rate remained significantly lower for transplant recipients. In addition, a report from the same group using a strategy of analyzing survival of paired kidneys from those with ESRD for more than two years versus less than six months found a survival advantage with less time on the transplant waiting list [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A relative increase in survival is also observed in patients with long waiting times. This was shown in a report of nearly 64,000 transplant candidates who started dialysis between 1995 and 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/44\">",
"     44",
"    </a>",
"    ]. The decrease in relative risk of death was greater among those with longer waiting times.",
"   </p>",
"   <p>",
"    A survival benefit with transplantation has been reported in patient populations outside of the United States. In Scotland, for example, one study reported the survival of 1732 patients wait-listed for a first kidney transplant in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/43\">",
"     43",
"    </a>",
"    ]. After an increased initial risk of death post-surgery, the long-term risk of death was markedly lower with renal transplantation (relative risk at 18 months of 0.18, 95% CI 0.08-0.42). Projected life expectancy was significantly higher in those who underwent transplantation (17.2 versus 5.8 years).",
"   </p>",
"   <p>",
"    A significant survival advantage is also observed among recipients of marginal kidneys, including kidneys donated after cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the survival of patients who received an extended donor kidney was compared with those who received standard therapy, which consisted of remaining on the waiting list and receiving an ideal donor kidney [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/47\">",
"       47",
"      </a>",
"      ]. At three years, survival was 17 percent lower for those who received an extended criteria donor kidney; particularly significant benefits were observed in patients older than 40 years, non-Hispanics, unsensitized patients, and those with diabetes or hypertension. This benefit with marginal kidneys is particularly significant for older and frailer transplant candidates [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational cohort study of 2575 kidney transplant waitlist patients evaluated the mortality risk of those who received a standard criteria kidney donated after cardiac death versus patients who continued on dialysis and waited for a standard criteria kidney donated after brain death [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/48\">",
"       48",
"      </a>",
"      ]. Compared to those who remained on dialysis, mortality was significantly lower among patients who received a kidney donated after cardiac death (hazard ratio 0.44: 95% CI 0.24-0.80).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeat renal transplantation after a failed primary transplant also may confer a survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In a large series of over 19,000 renal transplant recipients with primary allograft failure, repeat renal transplantation was associated with a 45 and 23 percent reduction in mortality at five years for patients with type 1 diabetes mellitus and those without diabetes, respectively, compared with those remaining on the waiting-list [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/50\">",
"     50",
"    </a>",
"    ]. Since patients with a failed primary transplant may comprise nearly 30 percent of current waiting lists, these added survival benefits with repeat transplantation have a significant impact upon overall mortality from end-stage renal disease.",
"   </p>",
"   <p>",
"    However, these data need to be interpreted with caution. Although the authors of the last study attempted to utilize a \"control\" group (ie, those listed for transplantation who did not actually receive a transplant), selection bias almost certainly played some role in these results. Patients listed for transplantation may not have been transplanted due to the development of intercurrent disease that led to death. This is a design flaw common to studies that rely upon the review of registry data.",
"   </p>",
"   <p>",
"    Despite some concerns about surgical risk, obese patients undergoing dialysis also derive a survival advantage with transplantation. Using data from the USRDS, significantly improved survival, compared with obese waiting list patients, was observed among obese recipients (with a body mass index of &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    of cadaveric or living donor kidneys (hazard ratios of 0.39 and 0.23, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduction in mortality among transplant recipients compared to dialysis patients is due in part to a decrease in cardiovascular events especially among diabetic patients. Transplantation reduces the risk of fatal and non-fatal cardiovascular complications compared with long-term dialysis among patients selected to be suitable transplant candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/23,25,28,52,53\">",
"     23,25,28,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reasons for improved survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying reasons for improved survival with renal transplantation compared with dialysis are unclear. However, since a functioning renal allograft more closely resembles a normal kidney than does maintenance dialysis therapy, it is possible that the survival benefit may result in part from improved clearance of uremic toxins.",
"   </p>",
"   <p>",
"    A possibility is that the recovery of renal function with a functional renal allograft lowers the inflammatory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oxidative state found in patients undergoing chronic dialysis. This has been reported in some studies for levels of C-reactive protein, TNF-alpha, and interleukin-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Some have postulated that this reduction is due in part to the chronic administration of anti-inflammatory agents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among diabetics, the restoration of near normal renal function following transplantation also retards the progression of microvascular disease by reducing the circulating levels of advanced glycosylation end products [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/57\">",
"     57",
"    </a>",
"    ]. These compounds accumulate in diabetic patients with renal failure and may contribute to the development of vascular disease, in part by crosslinking with collagen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link&amp;anchor=H2#H2\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another contributing factor may be that left ventricular hypertrophy tends to lessen after transplantation. Such improvement may decrease the risk of mortality from coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Decreased ongoing general inflammation and oxidative stress, which are associated with an increased risk of cardiovascular disease, may also contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17992/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=see_link\">",
"       \"Patient information: Kidney transplant (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"       \"Patient information: Planning for a kidney transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7590289\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kidney transplantation is the treatment of choice for selected patients with end-stage renal disease. Transplantation confers the highest survival benefit among all the different renal replacement therapies. A survival benefit has been observed among diabetic patients, African-Americans, obese patients and in patients in all age groups, as well as in those who are recipients of marginal kidneys. The reasons for improved survival with renal transplantation compared with dialysis are unclear. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Factors associated with patient survival'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Survival compared with Dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the survival benefit conferred by transplantation compared to dialysis, renal allograft recipients still have a high mortality rate compared with population controls. Post-transplantation survival rates vary based upon the source of the allograft, patient age, and the presence and degree of severity of comorbid conditions. Other factors that may contribute to survival rates include gender, race, and degree of immunosuppression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Factors associated with patient survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiovascular disease is the leading cause of death for adult renal allograft recipients. De novo heart failure is also common among patients after renal transplantation and is associated with poor survival. Among those who require intervention for coronary artery disease after transplantation, myocardial revascularization is associated with acceptable immediate and long-term survival and similar outcomes with percutaneous and surgical techniques. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cardiovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The survival of diabetic patients after renal transplantation is lower than that reported for nondiabetic patients due to the prevalence of extrarenal vascular disease. However survival among diabetic patients who have a transplant is still markedly better than that seen with dialysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diabetes mellitus'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=see_link\">",
"       \"Renal transplantation in diabetic nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections are the leading cause of mortality in the early posttransplant period and are related to the level of overall immunosuppression rather than the use of a specific immunosuppressive agent. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Overall immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The particular causes of death among transplant recipients has changed over time and varies with age. In one single center study, the percentages of deaths caused by cardiac disease, cancer, and stroke appear to have increased. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Causes of death'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/1\">",
"      Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/2\">",
"      Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/3\">",
"      Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/4\">",
"      Ojo AO, Port FK, Wolfe RA, et al. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994; 24:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/5\">",
"      Snyder JJ, Kasiske BL, Gilbertson DT, Collins AJ. A comparison of transplant outcomes in peritoneal and hemodialysis patients. Kidney Int 2002; 62:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/6\">",
"      Evans RW, Orians CE, Ascher NL. The potential supply of organ donors. An assessment of the efficacy of organ procurement efforts in the United States. JAMA 1992; 267:239.",
"     </a>",
"    </li>",
"    <li>",
"     Wolfe, R. The state of kidney transplantation in the United States. Semin Dial 18:453.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/8\">",
"      Arend SM, Mallat MJ, Westendorp RJ, et al. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997; 12:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/9\">",
"      Nogueira JM, Haririan A, Jacobs SC, et al. Cigarette smoking, kidney function, and mortality after live donor kidney transplant. Am J Kidney Dis 2010; 55:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/10\">",
"      Port FK, Dykstra DM, Merion RM, Wolfe RA. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant 2005; 5:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/11\">",
"      McCullough, KP, Keith, DS, Meyer, KH, Kidney and pancreas transplantation in the United States, 1998-2007: Access for patients with diabetes and end-stage renal disease. Am J Transplant Am J Transplant 2009; 9:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/12\">",
"      United States Renal Data System. 2003 Annual Data Report. Am J Kidney Dis 2004; 42(Suppl 5):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/13\">",
"      Becker BN, Becker YT, Pintar TJ, et al. Using renal transplantation to evaluate a simple approach for predicting the impact of end-stage renal disease therapies on patient survival: observed/expected life span. Am J Kidney Dis 2000; 35:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/14\">",
"      The 2003 SRTR report on the state of transplantation. Am J Transplant 2004; 4 (Suppl 9):54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/15\">",
"      Fabrizii V, Winkelmayer WC, Klauser R, et al. Patient and graft survival in older kidney transplant recipients: does age matter? J Am Soc Nephrol 2004; 15:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/16\">",
"      Keith DS, Demattos A, Golconda M, et al. Effect of donor recipient age match on survival after first deceased donor renal transplantation. J Am Soc Nephrol 2004; 15:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/17\">",
"      Wu C, Evans I, Joseph R, et al. Comorbid conditions in kidney transplantation: association with graft and patient survival. J Am Soc Nephrol 2005; 16:3437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/18\">",
"      Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004; 65:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/19\">",
"      Glanton CW, Kao TC, Cruess D, et al. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int 2003; 63:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/20\">",
"      Yeo FE, Villines TC, Bucci JR, et al. Cardiovascular risk in stage 4 and 5 nephropathy. Adv Chronic Kidney Dis 2004; 11:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/21\">",
"      Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82:603.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/23\">",
"      Cosio FG, Hickson LJ, Griffin MD, et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am J Transplant 2008; 8:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/24\">",
"      Herzog CA, Ma JZ, Collins AJ. Long-term survival of renal transplant recipients in the United States after acute myocardial infarction. Am J Kidney Dis 2000; 36:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/25\">",
"      Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/26\">",
"      Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. Circulation 2004; 109:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/27\">",
"      Ferguson ER, Hudson SL, Diethelm AG, et al. Outcome after myocardial revascularization and renal transplantation: a 25-year single-institution experience. Ann Surg 1999; 230:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/28\">",
"      Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis 2005; 46:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/29\">",
"      Lentine KL, Schnitzler MA, Abbott KC, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol 2006; 1:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/30\">",
"      Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004; 15 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/31\">",
"      Lufft V, Dannenberg B, Schlitt HJ, et al. Cardiovascular morbidity and mortality in patients with diabetes mellitus type I after kidney transplantation: a case-control study. Clin Nephrol 2004; 61:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/32\">",
"      Rubin RH. Infectious disease complications of renal transplantation. Kidney Int 1993; 44:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/33\">",
"      Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/34\">",
"      Woo YM, Jardine AG, Clark AF, et al. Early graft function and patient survival following cadaveric renal transplantation. Kidney Int 1999; 55:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/35\">",
"      Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/36\">",
"      Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/37\">",
"      Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/38\">",
"      Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/39\">",
"      Grenfell A, Bewick M, Snowden S, et al. Renal replacement for diabetic patients: experience at King's College Hospital 1980-1989. Q J Med 1992; 85:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/40\">",
"      Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/41\">",
"      Rabbat CG, Thorpe KE, Russell JD, Churchill DN. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000; 11:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/42\">",
"      Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001; 12:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/43\">",
"      Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 2005; 16:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/44\">",
"      Gill JS, Tonelli M, Johnson N, et al. The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. Kidney Int 2005; 68:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/45\">",
"      Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/46\">",
"      Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/47\">",
"      Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005; 294:2726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/48\">",
"      Snoeijs MG, Schaubel DE, Hen&eacute; R, et al. Kidneys from donors after cardiac death provide survival benefit. J Am Soc Nephrol 2010; 21:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/49\">",
"      Schold JD, Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Am Soc Nephrol 2006; 1:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/50\">",
"      Ojo A, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation 1998; 66:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/51\">",
"      Rao PS, Schaubel DE, Wei G, Fenton SS. Evaluating the survival benefit of kidney retransplantation. Transplantation 2006; 82:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/52\">",
"      Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/53\">",
"      Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008; 3:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/54\">",
"      Cueto-Manzano AM, Morales-Buenrostro LE, Gonz&aacute;lez-Espinoza L, et al. Markers of inflammation before and after renal transplantation. Transplantation 2005; 80:47.",
"     </a>",
"    </li>",
"    <li>",
"     Ducloux, D, Kazory, A, Chalopin, JM, et al. Predicting coronary heart disease in renal transplant recipients: a prospective study.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/56\">",
"      Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/57\">",
"      Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/58\">",
"      Lopez-Gomez JM, Verde E, Perez-Garcia R. Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients. Kidney Int Suppl 1998; 68:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/59\">",
"      McGregor E, Jardine AG, Murray LS, et al. Pre-operative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant 1998; 13:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17992/abstract/60\">",
"      Simmons EM, Langone A, Sezer MT, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005; 79:914.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7347 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-ED3CA7AB47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17992=[""].join("\n");
var outline_f17_36_17992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7590289\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTORS ASSOCIATED WITH PATIENT SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Allograft source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient and deceased donor age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overall immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Allograft function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CAUSES OF DEATH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SURVIVAL COMPARED WITH DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reasons for improved survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7590289\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=related_link\">",
"      Differential diagnosis of renal allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=related_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=related_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/29/43480?source=related_link\">",
"      Renal transplantation and the elderly patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36472?source=related_link\">",
"      Renal transplantation in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_36_17993="Simvastatin: Drug information";
var content_f17_36_17993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Simvastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/17/11541?source=see_link\">",
"    see \"Simvastatin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/12/44231?source=see_link\">",
"    see \"Simvastatin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F12889403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Simvastatin and Dose-Related Myopathy: Health Canada Issues Notice",
"     </span>",
"     <span class=\"collapsible-date\">",
"      November 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada, in conjunction with Merck Canada Inc, has issued notice to Canadian healthcare professionals regarding increased risks of myopathy associated with high-dose (80 mg/day) simvastatin (Zocor&reg;).  The simvastatin Canadian product monograph recommends limiting the dose to &le;40 mg/day; an alternative treatment should be used for patients unable to reach their LDL-C goal with this dosage recommendation. Higher doses (80 mg/day) of simvastatin are restricted to patients requiring chronic use and without evidence of myopathy or who are at high risk of cardiovascular complications and unable to tolerate other statins. Specific recommendations regarding simvastatin use and dosage with concomitant medications (eg, verapamil, amiodarone, amlodipine, fusidic acid) and grapefruit juice are also included in the product labeling.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at  file://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/zocor_hpc-cps-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zocor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Simvastatin&reg;;",
"     </li>",
"     <li>",
"      Ava-Simvastatin;",
"     </li>",
"     <li>",
"      CO Simvastatin;",
"     </li>",
"     <li>",
"      Dom-Simvastatin;",
"     </li>",
"     <li>",
"      JAMP-Simvastatin;",
"     </li>",
"     <li>",
"      Mint-Simvastatin;",
"     </li>",
"     <li>",
"      Mylan-Simvastatin;",
"     </li>",
"     <li>",
"      Nu-Simvastatin;",
"     </li>",
"     <li>",
"      PHL-Simvastatin;",
"     </li>",
"     <li>",
"      PMS-Simvastatin;",
"     </li>",
"     <li>",
"      Q-Simvastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Simvastatin;",
"     </li>",
"     <li>",
"      ratio-Simvastatin;",
"     </li>",
"     <li>",
"      Riva-Simvastatin;",
"     </li>",
"     <li>",
"      Sandoz-Simvastatin;",
"     </li>",
"     <li>",
"      Simvastatin-Odan;",
"     </li>",
"     <li>",
"      Taro-Simvastatin;",
"     </li>",
"     <li>",
"      Teva-Simvastatin;",
"     </li>",
"     <li>",
"      Zocor&reg;;",
"     </li>",
"     <li>",
"      ZYM-Simvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and the patient's response; adjustments should be made at intervals of 4 weeks or more; doses may need adjusted based on concomitant medications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note: Dosing limitation: Simvastatin 80 mg is limited to patients that have been taking this dose for &gt;12 consecutive months without evidence of myopathy and are not currently taking or beginning to take a simvastatin dose-limiting or contraindicated interacting medication.",
"     </b>",
"     If patient is unable to achieve low-density lipoprotein-cholesterol (LDL-C)  goal using the 40 mg dose of simvastatin, increasing to 80 mg dose is not recommended. Instead, switch patient to an alternative LDL-C-lowering treatment providing greater LDL-C reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Homozygous familial hypercholesterolemia:",
"     </b>",
"     Oral: 40 mg once daily in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of cardiovascular events, hyperlipidemias:",
"     </b>",
"     Oral: 10-20 mg once daily in the evening; range: 5-40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients requiring only moderate reduction of LDL-C:",
"     </i>",
"     May be started at 5-10 mg once daily in the evening; adjust to achieve recommended LDL-C goal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients requiring reduction of &gt;40% of  LDL-C:",
"     </i>",
"     May be started at 40 mg once daily in the evening; adjust to achieve recommended LDL-C goal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients with CHD or at high risk for cardiovascular events (patients with diabetes, PVD, history of stroke or other cerebrovascular disease):",
"     </i>",
"     Dosing should be started at 40 mg once daily in the evening; start simultaneously with diet therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for simvastatin with concomitant medications:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Patients currently tolerating and requiring a dose of simvastatin 80 mg who require initiation of an interacting drug with a dose cap for simvastatin should be switched to an alternative statin with less potential for drug-drug interaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Amiodarone, amlodipine, or ranolazine:",
"     </i>",
"     Simvastatin dose should",
"     <b>",
"      not",
"     </b>",
"     exceed 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Diltiazem, dronedarone, or verapamil:",
"     </i>",
"     Simvastatin dose should",
"     <b>",
"      not",
"     </b>",
"     exceed 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lomitapide:",
"     </i>",
"     Simvastatin dose should not exceed 20 mg/day (or 40 mg daily for those who previously tolerated simvastatin 80 mg daily for &ge;1 year without evidence of muscle toxicity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in Chinese patients on niacin doses &ge;1 g/day:",
"     </b>",
"     Use caution with simvastatin doses exceeding 20 mg/day; because of an increased risk of myopathy, do not administer simvastatin 80 mg concurrently.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/12/44231?source=see_link\">",
"      see \"Simvastatin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HeFH:",
"     </b>",
"     Oral: Children 10-17 years (females &gt;1 year postmenarche): 10 mg once daily in the evening; range: 10-40 mg/day (maximum: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant medications:",
"     </b>",
"     With concomitant amiodarone, amlodipine, diltiazem, dronedarone, lomitapide, ranolazine, or verapamil: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and the patient's response; adjustments should be made at intervals of 4 weeks or more; doses may need adjusted based on concomitant medications",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: Maximum reductions in LDL-cholesterol may be achieved with daily dose &le;20 mg.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F221309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Manufacturer&rsquo;s recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate renal impairment: No dosage adjustment necessary; simvastatin does not undergo significant renal excretion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe renal impairment: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial: 5 mg/day with close monitoring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternative recommendation: No dosage adjustment necessary for any degree of renal impairment (Aronoff, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zocor&reg;: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals. Administer in the evening for maximal efficacy.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used with dietary therapy for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Secondary prevention of cardiovascular events in hypercholesterolemic patients with established coronary heart disease (CHD) or at high risk for CHD: To reduce cardiovascular morbidity (myocardial infarction, coronary/noncoronary revascularization procedures) and mortality; to reduce the risk of stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hyperlipidemias: To reduce elevations in total cholesterol (total-C), LDL-C, apolipoprotein B, triglycerides, and VLDL-C, and to increase HDL-C in patients with primary hypercholesterolemia (elevations of 1 or more components are present in Fredrickson type IIa, IIb, III, and IV hyperlipidemias); treatment of homozygous familial hypercholesterolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Heterozygous familial hypercholesterolemia (HeFH): In adolescent patients (10-17 years of age, females &gt;1 year postmenarche) with HeFH having LDL-C &ge;190 mg/dL",
"     <b>",
"      or",
"     </b>",
"     LDL-C &ge;160 mg/dL with positive family history of premature cardiovascular disease (CVD), or 2 or more CVD risk factors in the adolescent patient",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F221358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Simvastatin may be confused with atorvaSTATin, nystatin, pitavastatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zocor&reg; may be confused with Cozaar&reg;, Lipitor&reg;, Zoloft&reg;, ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cardin [Poland] may be confused with Cardem brand name for celiprolol [Spain]; Cardene brand name for nicardipine [U.S., Great Britain, Netherlands]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation (6%; placebo 5%), edema (3%; placebo 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 7%), vertigo (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Eczema (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (7%), constipation (2% to 7%), gastritis (5%), nausea (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (&gt;3 x ULN; 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (&gt;3 x normal; 5%), myalgia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infections (9%), bronchitis (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, alopecia, amnesia (reversible), anaphylaxis, anemia, angioedema, arthralgia, arthritis, blood glucose increased, chills, cognitive impairment (reversible), confusion (reversible), depression, dermatomyositis, diabetes mellitus (new onset), diarrhea, dizziness, dryness of skin/mucous membranes, dyspepsia, dyspnea, eosinophilia, erythema multiforme, ESR increased, fever, flatulence, flushing, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased, GGT increased, hemolytic anemia, hepatic failure, hepatitis, hypersensitivity reaction, jaundice, leukopenia, malaise, memory disturbance (reversible), memory impairment (reversible), muscle cramps, nail changes, nodules, pancreatitis, paresthesia, peripheral neuropathy, photosensitivity, polymyalgia rheumatica, positive ANA, pruritus, purpura, rash, rhabdomyolysis, skin discoloration, Stevens-Johnson syndrome, systemic lupus erythematosus-like syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vasculitis, vomiting, weakness",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Additional class-related events or case reports (not necessarily reported with simvastatin therapy): Alteration in taste, anorexia, anxiety, bilirubin increased, cataracts, cholestatic jaundice, cirrhosis, decreased libido, depression, erectile dysfunction/impotence, facial paresis, fatty liver, fulminant hepatic necrosis, gynecomastia, hepatoma, hyperbilirubinemia, immune-mediated necrotizing myopathy (IMNM), impaired extraocular muscle movement, increased CPK (&gt;10 x normal), interstitial lung disease, ophthalmoplegia, peripheral nerve palsy, psychic disturbance, renal failure (secondary to rhabdomyolysis), thyroid dysfunction, tremor, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to simvastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole, protease inhibitors [including boceprevir and telaprevir], telithromycin), cyclosporine, danazol, and gemfibrozil; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however,  the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart simvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with high doses (80 mg), concurrent use of other lipid-lowering medications (fibric acid derivatives, or niacin at doses &ge;1 g/day), other interacting drugs (eg, moderate-to-strong CYP3A4 inhibitors), age &ge;65 years, female gender, uncontrolled hypothyroidism, and renal dysfunction. Use with caution in patients taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. Use is contraindicated with active liver disease and with unexplained transaminase elevations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment (creatinine clearance not defined); initial dosage adjustment is necessary; monitor closely. Initial dosage adjustment is not necessary in mild-to-moderate impairment. Renal impairment may also increase risk for myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of simvastatin with some drugs may require cautious use, may not be recommended, may require dosage adjustments, or may be contraindicated. If concurrent use of a contraindicated interacting medication is unavoidable, treatment with simvastatin should be suspended during use or consider the use of an alternative HMG-CoA reductase inhibitor void of CYP3A4 metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special Populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chinese patients: Do not use high dose simvastatin (80 mg) if concurrently taking niacin &ge;1 g/day; concomitant use may increase risk of myopathy in Chinese patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &ge;65 years of age; these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F221344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AmLODIPine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem. Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Simvastatin. Management: Limit simvastatin to a max of 10 mg/day (in adults). Increase monitoring for signs of simvastatin toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May increase the serum concentration of Simvastatin. Specifically, Simvastatin lactone concentrations may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May decrease the metabolism of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Simvastatin. Management: Reduce the recommended simvastatin dose by 50%. Generally, limit the maximum adult simvastatin dose to 20 mg/day. A 40 mg/day dose can be considered in patients who previously received 80 mg/day for at least a year without evidence of muscle toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Simvastatin. Management: Avoid simvastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of ranolazine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Simvastatin. Management: Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Simvastatin. Management: Avoid concurrent use of verapamil with simvastatin when possible.   If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F221299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Excessive ethanol consumption has the potential to cause hepatic effects. Management: Avoid or limit ethanol consumption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Simvastatin serum concentration may be increased when taken with grapefruit juice. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice. Management: Avoid concurrent intake of large quantities of grapefruit juice (&gt;1 quart/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease simvastatin levels. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1792946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards. If pregnancy occurs during treatment, discontinue simvastatin immediately.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F221313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F221288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk is unknown, but would be expected; other medications in this class are excreted in human milk. Breast-feeding is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F802418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     May be taken without regard to meals. Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F221287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Simvastatin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (90): $189.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $253.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $442.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $442.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (90): $442.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zocor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $85.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $114.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $199.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $199.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $199.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F221276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Lipid panel should be analyzed after 4 weeks of therapy and periodically thereafter.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F221289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avastinee (HK);",
"     </li>",
"     <li>",
"      Bestatin (TH);",
"     </li>",
"     <li>",
"      Biosim (IN);",
"     </li>",
"     <li>",
"      Cholestat (ID);",
"     </li>",
"     <li>",
"      Clinfar (BR);",
"     </li>",
"     <li>",
"      Colesken (MX);",
"     </li>",
"     <li>",
"      Corstat (HK);",
"     </li>",
"     <li>",
"      Covastin (HK, MY, SG);",
"     </li>",
"     <li>",
"      Decrelip (PY);",
"     </li>",
"     <li>",
"      Ecuvas (EC);",
"     </li>",
"     <li>",
"      Esvat (ID);",
"     </li>",
"     <li>",
"      Ethicol (ID);",
"     </li>",
"     <li>",
"      Eucor (TH);",
"     </li>",
"     <li>",
"      Euvasten (PH);",
"     </li>",
"     <li>",
"      Forcad (PH);",
"     </li>",
"     <li>",
"      Husimba (KP);",
"     </li>",
"     <li>",
"      Ifistatin (SG);",
"     </li>",
"     <li>",
"      Kardak (HK);",
"     </li>",
"     <li>",
"      Klonastin (AR);",
"     </li>",
"     <li>",
"      Lesvatin (ID);",
"     </li>",
"     <li>",
"      Lipaco (MY);",
"     </li>",
"     <li>",
"      Lipecor (KP);",
"     </li>",
"     <li>",
"      Lipex (AU, HR, NZ);",
"     </li>",
"     <li>",
"      Lipidoff (TW);",
"     </li>",
"     <li>",
"      Lipinorm (ID);",
"     </li>",
"     <li>",
"      Liponorm (IT);",
"     </li>",
"     <li>",
"      Lipovas (JP);",
"     </li>",
"     <li>",
"      Lochol (TH);",
"     </li>",
"     <li>",
"      Lodales (FR);",
"     </li>",
"     <li>",
"      Luoqi (CL);",
"     </li>",
"     <li>",
"      Mersivas (ID);",
"     </li>",
"     <li>",
"      Nimicor (CN);",
"     </li>",
"     <li>",
"      Nor-Vastina (DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Orovas (PH);",
"     </li>",
"     <li>",
"      Priacin (SG);",
"     </li>",
"     <li>",
"      Pusarat (MX);",
"     </li>",
"     <li>",
"      Ransim (AU);",
"     </li>",
"     <li>",
"      Rechol (ID);",
"     </li>",
"     <li>",
"      Rezostatin (TW);",
"     </li>",
"     <li>",
"      Roco (KP);",
"     </li>",
"     <li>",
"      Simaspen (ZA);",
"     </li>",
"     <li>",
"      Simbado (ID);",
"     </li>",
"     <li>",
"      Simcard (HK);",
"     </li>",
"     <li>",
"      Simchol (ID);",
"     </li>",
"     <li>",
"      Simlo (MX);",
"     </li>",
"     <li>",
"      Simovil (IL);",
"     </li>",
"     <li>",
"      Simplaqor (MX);",
"     </li>",
"     <li>",
"      SimStatin (NZ);",
"     </li>",
"     <li>",
"      Simtin (HK, MY, SG);",
"     </li>",
"     <li>",
"      Simva (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Simvabell (AU);",
"     </li>",
"     <li>",
"      Simvacor (IL, MY, SG);",
"     </li>",
"     <li>",
"      Simvahex (PH);",
"     </li>",
"     <li>",
"      Simvahexal (AU, TW);",
"     </li>",
"     <li>",
"      Simvalord (KP);",
"     </li>",
"     <li>",
"      Simvar (AU);",
"     </li>",
"     <li>",
"      Simvastan (KP);",
"     </li>",
"     <li>",
"      Simvastar (KP);",
"     </li>",
"     <li>",
"      Simvata (KP);",
"     </li>",
"     <li>",
"      Simvatin (AE, BH, CY, EG, IQ, IR, JO, KP, KW, LB, LY, OM, QA, SA, SY, YE, ZA);",
"     </li>",
"     <li>",
"      Simvaxon (IL);",
"     </li>",
"     <li>",
"      Simvor (TH);",
"     </li>",
"     <li>",
"      Sinty (TW);",
"     </li>",
"     <li>",
"      Sinvacor (IT);",
"     </li>",
"     <li>",
"      Sivas (KP);",
"     </li>",
"     <li>",
"      Sivastin (IT);",
"     </li>",
"     <li>",
"      Statin (CO);",
"     </li>",
"     <li>",
"      Stavid (MY);",
"     </li>",
"     <li>",
"      Torio (TH);",
"     </li>",
"     <li>",
"      Tulip (MX);",
"     </li>",
"     <li>",
"      Valemia (ID);",
"     </li>",
"     <li>",
"      Vascor (MY, SG, TH);",
"     </li>",
"     <li>",
"      Vasilip (HK);",
"     </li>",
"     <li>",
"      Vasotenal (PE);",
"     </li>",
"     <li>",
"      Vidastat (PH);",
"     </li>",
"     <li>",
"      Zeid (MX);",
"     </li>",
"     <li>",
"      Zetina (EC);",
"     </li>",
"     <li>",
"      Zimmex (TH);",
"     </li>",
"     <li>",
"      Zimstat (AU);",
"     </li>",
"     <li>",
"      Zocor (AR, AU, BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IT, JM, KE, KP, LR, LU, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, PA, PE, PH, PK, PL, PT, SC, SD, SL, SN, SR, SV, TH, TN, TT, TW, TZ, UG, UY, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Zocor HP (PH);",
"     </li>",
"     <li>",
"      Zocord (AT, SE);",
"     </li>",
"     <li>",
"      Zorced (MX);",
"     </li>",
"     <li>",
"      Zovast (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Simvastatin is a methylated derivative of lovastatin that acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: &gt;3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &lt;5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1.3-2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (60%); urine (13%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2012, 97(9):2969-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/22962670/pubmed\" id=\"22962670\" target=\"_blank\">",
"        22962670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark CM Jr and Lee DA, &ldquo;Prevention and Treatment of the Complications of Diabetes Mellitus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(18):1201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/7700316/pubmed\" id=\"7700316\" target=\"_blank\">",
"        7700316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dagogo-Jack S and Santiago JV, &ldquo;Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Interventions,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1997, 157(16):1802-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/9290539/pubmed\" id=\"9290539\" target=\"_blank\">",
"        9290539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Lemos JA, Blazing MA, Wiviott SD, et al, &ldquo;Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 292(11):1307-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/15337732/pubmed\" id=\"15337732\" target=\"_blank\">",
"        15337732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fernandez AB, Karas RH, Alsheikh-Ali AA, et al, &ldquo;Statins and Interstitial Lung Disease: A Systematic Review of the Literature and of Food and Drug Administration Adverse Event Reports,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 134(4):824-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/18689579/pubmed\" id=\"18689579\" target=\"_blank\">",
"        18689579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fonarow GC, French WJ, Parsons LS, et al, &ldquo;Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2001, 103(1):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/11136683/pubmed\" id=\"11136683\" target=\"_blank\">",
"        11136683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaster B and Hirsch IB, &ldquo;The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(2):134-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/9448551/pubmed\" id=\"9448551\" target=\"_blank\">",
"        9448551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haffner SM, Alexander CM, Cook TJ, et al, &ldquo;Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels: Subgroup Analyses in the Scandinavian Simvastatin Survival Study,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1999, 159(22):2661-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/10597756/pubmed\" id=\"10597756\" target=\"_blank\">",
"        10597756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heeschen C, Hamm CW, Laufs U, et al, &ldquo;Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(12):1446-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/11914253/pubmed\" id=\"11914253\" target=\"_blank\">",
"        11914253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeManach Y, Godet G, Coriat P, et al, &ldquo;The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 104(6):1326-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/17513620/pubmed\" id=\"17513620\" target=\"_blank\">",
"        17513620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(11):913-27; published erratum appears in",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2006, 22(12):1077.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/16971976/pubmed\" id=\"16971976\" target=\"_blank\">",
"        16971976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;MRC/BHF Heart Protection Study of Cholesterol Lowering With Simvastatin in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. Heart Protection Study Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9326):7-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/12114036/pubmed\" id=\"12114036\" target=\"_blank\">",
"        12114036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al, &ldquo;ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2002, 33(9):2337-41. Available at file://stroke.ahajournals.org/cgi/content/short/33/9/2337",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/12215610/pubmed\" id=\"12215610\" target=\"_blank\">",
"        12215610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pearson TA, Mensah GA, Alexander RW, et al, &ldquo;Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(3):499-511.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/12551878/pubmed\" id=\"12551878\" target=\"_blank\">",
"        12551878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peto R, Emberson J, Landray M, et al, &ldquo;Analysis of Cancer Data From Three Ezetimibe Trials,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(13):1357-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/18765432/pubmed\" id=\"18765432\" target=\"_blank\">",
"        18765432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips BG, Yim JM, Brown EJ Jr, et al, &ldquo;Pharmacologic Profile of Survivors of Acute Myocardial Infarction at United States Academic Hospitals,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1996, 131(5):872-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/8615304/pubmed\" id=\"8615304\" target=\"_blank\">",
"        8615304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Bax JJ, Kertai MD, et al, &ldquo;Statins Are Associated With a Reduced Incidence of Perioperative Mortality in Patients Undergoing Major Noncardiac Vascular Surgery,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(14):1848-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/12695283/pubmed\" id=\"12695283\" target=\"_blank\">",
"        12695283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359:2195-2207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossebo AB, Pederson TR, Boman K, et al, &ldquo;Intensive Lipid Lowering With Simvastatin and Ezetimibe in Aortic Stenosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(13):1343-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/18765433 /pubmed\" id=\"18765433 \" target=\"_blank\">",
"        18765433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scandinavian Simvastatin Survival Study, &ldquo;Randomized Trial of Cholesterol Lowering in 4444 Patients With Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1994, 344(8934):1383-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/7968073/pubmed\" id=\"7968073\" target=\"_blank\">",
"        7968073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shepherd J, Cobbe SM, Ford I, et al, &ldquo;Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. West of Scotland Coronary Prevention Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(20):1301-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/7566020/pubmed\" id=\"7566020\" target=\"_blank\">",
"        7566020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, \"Intensive Lowering of LDL Cholesterol With 80 mg versus 20 mg Simvastatin Daily in 12,064 Survivors of Myocardial Infarction: A Double-Blind Randomised Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9753):1658-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/21067805/pubmed\" id=\"21067805\" target=\"_blank\">",
"        21067805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 106(25):3143-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/36/17993/abstract-text/12485966/pubmed\" id=\"12485966\" target=\"_blank\">",
"        12485966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9923 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17993=[""].join("\n");
var outline_f17_36_17993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12889403\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221302\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221303\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221350\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221307\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221328\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221308\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221309\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221278\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221263\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221282\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221281\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221358\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221348\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221285\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221267\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221344\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221272\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221299\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221274\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1792946\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221313\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221288\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802418\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221287\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221276\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221289\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221266\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221284\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9923\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9923|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/17/11541?source=related_link\">",
"      Simvastatin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/12/44231?source=related_link\">",
"      Simvastatin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_36_17994="Prevention and treatment of glucocorticoid-induced osteoporosis";
var content_f17_36_17994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of glucocorticoid-induced osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/36/17994/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/36/17994/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/36/17994/contributors\">",
"     Kenneth G Saag, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/36/17994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/36/17994/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/36/17994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/36/17994/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/36/17994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy is associated with an appreciable risk of bone loss, which is most pronounced in the first few months of use. In addition, glucocorticoids increase fracture risk, and fractures occur at higher bone mineral density values than occur in postmenopausal osteoporosis. The increased risk of fracture has been reported with doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent as low as 2.5 to 7.5 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, glucocorticoid-induced bone loss should be treated aggressively, particularly in those already at high risk for fracture (elderly, prior fragility fracture). In other individuals, clinical risk factor and bone density assessment may help guide therapy. The prevention and treatment of glucocorticoid-induced bone loss will be reviewed here. The clinical features are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of the prevention and treatment strategies for glucocorticoid-induced bone loss are similar to those used to prevent and treat other causes of osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention and treatment strategies consist of attempts to reverse the glucocorticoid excess by decreasing the dose of exogenous glucocorticoid or curing the cause of endogenous cortisol overproduction, calcium and vitamin D supplementation, and in some patients, pharmacologic therapy to minimize further bone loss or reverse it. In an attempt to minimize bone loss, certain general principles should be followed in all patients receiving all doses of glucocorticoids for a duration of &ge;3 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The glucocorticoid dose and the duration of therapy should be as low as possible, because even what are thought to be replacement doses or chronic inhaled glucocorticoids can cause bone loss [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/4\">",
"       4",
"      </a>",
"      ]. Alternative therapy should be used whenever possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link&amp;anchor=H11#H11\">",
"       \"Major side effects of inhaled glucocorticoids\", section on 'Osteoporosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When glucocorticoids are given, topical therapy (such as inhaled glucocorticoids or glucocorticoid enemas for asthma or bowel disease, respectively) is preferred over enteral or parenteral glucocorticoids, whenever possible.",
"     </li>",
"     <li>",
"      Patients should be encouraged to do weight-bearing exercises to prevent both bone loss and muscle atrophy.",
"     </li>",
"     <li>",
"      Patients should avoid smoking and excess alcohol.",
"     </li>",
"     <li>",
"      Patients should take measures to prevent falls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CALCIUM AND VITAMIN D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids induce negative calcium balance by decreasing intestinal calcium absorption and increasing urinary calcium excretion. Therefore, calcium supplementation may attenuate bone loss in patients taking glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. We agree with the American College of Rheumatology (ACR) Task Force osteoporosis guidelines, which suggest that patients taking glucocorticoids (any dose with an anticipated duration of &ge;3 months) maintain a total calcium intake of 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and vitamin D intake of 800 International",
"    <span class=\"nowrap\">",
"     Units/day",
"    </span>",
"    through either diet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a meta-analysis of five randomized trials comparing calcium and vitamin D (cholecalciferol or an active vitamin D metabolite) to calcium alone or placebo in patients taking glucocorticoids, there was significant improvement in lumbar spine and radial BMD in the calcium and vitamin D group (weighted mean difference between treatment and control groups 2.6 and 2.5 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/7\">",
"     7",
"    </a>",
"    ]. Two of the trials reported the incidence of new, non-traumatic fractures. Although calcium plus vitamin D reduced the incidence of fracture, the results were not statistically significant (odds ratio 0.6, 95% CI 0.1-2.4).",
"   </p>",
"   <p>",
"    In one of the larger studies included in the meta-analysis, 96 patients with rheumatoid arthritis receiving low-dose glucocorticoid therapy (mean",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose 5.6 mg daily) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    (1000 mg of elemental calcium daily) plus vitamin D3 (500",
"    <span class=\"nowrap\">",
"     IU/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/8\">",
"     8",
"    </a>",
"    ]. The between group difference in the annual rate of change in BMD was 2.65 percent (95% CI 0.73-4.57) and 2.08 percent (95% CI 0.43-3.73), for the spine and trochanter, respectively, favoring calcium and vitamin D supplementation.",
"   </p>",
"   <p>",
"    Although calcium and vitamin D supplementation is necessary, it is generally not sufficient to prevent bone loss and fracture in patients taking high-dose glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Pharmacologic therapy is often required. (See",
"    <a class=\"local\" href=\"#H622797\">",
"     'Candidates for pharmacologic therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H5\">",
"     'Bisphosphonates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Active vitamin D metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D metabolites that are more active than vitamin D itself, such as calcitriol and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/14/37093?source=see_link\">",
"     alfacalcidol",
"    </a>",
"    , have also been evaluated for the prevention and treatment of glucocorticoid-induced bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/13\">",
"     13",
"    </a>",
"    ]. Calcitriol (1,25-dihydroxyvitamin D, the most active metabolite of vitamin D) plus calcium protect against spine bone loss more than calcium alone in patients taking glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. A meta-analysis of five trials of active vitamin D metabolites in patients exposed to corticosteroids reported a beneficial effect of vitamin D metabolites on lumbar spine BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/15\">",
"     15",
"    </a>",
"    ]. There was insufficient data to address fracture prevention.",
"   </p>",
"   <p>",
"    Active vitamin D metabolites are less commonly used, however, because of the risks of hypercalcemia and hypercalciuria in patients whose urinary calcium excretion is already increased, and because more effective therapies are available [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/10,16-18\">",
"     10,16-18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Bisphosphonates versus active D metabolites'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622797\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the highest risk for fracture are the ones most likely to benefit from drug therapy. Thus, selection of patients based upon fracture risk, as determined by a combination of bone mineral density (BMD) and clinical risk factors, is desirable. For patients without established osteoporosis (history of fragility fracture or BMD T-score &le;-2.5), fracture risk can be assessed using the World health Organization Fracture Risk Assessment Tool (",
"    <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"     FRAX",
"    </a>",
"    ). FRAX estimates the 10-year probability of fracture for untreated postmenopausal women and men &ge;50 years, using femoral neck BMD and clinical risk factors, including glucocorticoid exposure. In the United States, a reasonable cut point to indicate high risk is a 10-year probability of hip or combined major osteoporotic fracture of &ge;3 and 20 percent, respectively. Fracture risk assessment, including the FRAX tool and its limitations, is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link&amp;anchor=H5#H5\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical application of fracture risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach described below is largely in agreement with various guidelines, which collectively suggest pharmacologic therapy for patients based upon assessment of BMD and clinical risk factors for fracture. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Guidelines'",
"    </a>",
"    below.) However, some patients receiving glucocorticoids are at high-risk, even if they fail to meet the FRAX criteria for intervention. As an example, for patients with clinical risk factors for fracture, low lumbar spine BMD, but normal femoral neck BMD, FRAX is likely to underestimate fracture risk. In addition, FRAX does not account for glucocorticoid dose or duration. Thus, intervention guidelines with or without the use of FRAX provide only general clinical guidance. Treatment should remain individualized through shared decision-making between patient and clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622960\">",
"    <span class=\"h2\">",
"     Established osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men &ge;50 years and postmenopausal women (who are initiating or are chronically treated with any dose of glucocorticoids for any duration) who have osteoporosis (previous fragility fracture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a BMD T-score &le;-2.5) at initial assessment, we recommend pharmacologic therapy. This recommendation is based upon randomized trial data showing that pharmacologic therapy improves bone mineral density (BMD) in patients taking glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] and additional randomized trial data showing that pharmacologic therapy reduces fracture in men and postmenopausal women with osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/21\">",
"     21",
"    </a>",
"    ]. Such patients should receive treatment for osteoporosis even in the absence of glucocorticoid treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622982\">",
"    <span class=\"h2\">",
"     Osteoporosis prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the treatment of high risk men &ge;50 years and postmenopausal women who are initiating or are chronically treated with any dose of glucocorticoids for any duration and have T-scores between -1.0 and -2.5, we suggest pharmacologic therapy. A reasonable cut point to indicate high risk that may be cost-effective in some settings is a FRAX calculated 10-year probability of hip or combined major osteoporotic fracture of &ge;3 or 20 percent, respectively. For postmenopausal women and men &gt;50 years who have a FRAX calculated absolute risk below these cut points, we suggest pharmacologic therapy if they are taking &ge;7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent for an anticipated duration of &ge;3 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622811\">",
"    <span class=\"h2\">",
"     Premenopausal women and younger men",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FRAX tool was not developed for use in premenopausal women or men &lt;40 years. In premenopausal women and younger men included in clinical trials for glucocorticoid-induced osteoporosis, fractures were generally infrequent in both treated and control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/12,22,23\">",
"     12,22,23",
"    </a>",
"    ]. Fracture risk in these patients taking glucocorticoids is not clearly defined and may differ from reported fracture risk in other glucocorticoid-treated populations. In the absence of definitive data, pharmacologic therapy needs to be individualized in premenopausal women and younger men. Potential short- and long-term risks, as well as potential effects on the fetus, should be considered as part of the decision to use bisphosphonates or teriparatide for the treatment of premenopausal osteoporosis.",
"   </p>",
"   <p>",
"    We recommend pharmacologic therapy for women with fragility fractures while receiving glucocorticoids (7.5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent for &ge;3 months) who do not need estrogen replacement therapy because they have normal menstrual function. For similar women who do not have a fragility fracture but have accelerated bone loss (&ge;4",
"    <span class=\"nowrap\">",
"     percent/year)",
"    </span>",
"    while receiving glucocorticoids, we also suggest pharmacologic therapy.",
"   </p>",
"   <p>",
"    For men &lt;50 years of age who have a fragility fracture while receiving glucocorticoids (7.5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent for &ge;3 months),",
"    <strong>",
"    </strong>",
"    we recommend pharmacologic therapy. For similar men who do not have a fragility fracture but have accelerated bone loss (&ge;4",
"    <span class=\"nowrap\">",
"     percent/year),",
"    </span>",
"    we also suggest pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BISPHOSPHONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For postmenopausal women and men, we favor bisphosphonates, and in particular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , for the prevention and treatment of glucocorticoid-induced bone loss. For patients who cannot tolerate or have difficulty with the dosing requirements of oral bisphosphonates, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    is an alternative.",
"   </p>",
"   <p>",
"    There are substantial data supporting the use of antiresorptive agents, such as the bisphosphonates, for the prevention and treatment of glucocorticoid-induced bone loss. In a meta-analysis of 13 randomized trials evaluating bisphosphonates for the prevention and treatment of glucocorticoid-induced osteoporosis (GIO), there was significant improvement in lumbar spine (weighted mean difference 4.3 percent) and femoral neck BMD (weighed mean difference 2.1 percent) between the treatment and placebo groups. The reduction in risk of vertebral fracture was not significant (odds ratio 0.76, 95% CI 0.37-1.53) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies demonstrating the benefits of bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis included some premenopausal women. In premenopausal women included in clinical trials for glucocorticoid-induced osteoporosis, fractures were generally infrequent in both treated and control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/12,22,23\">",
"     12,22,23",
"    </a>",
"    ]. However, bisphosphonates are an option for premenopausal women with fragility fractures or accelerated bone loss (&ge;4",
"    <span class=\"nowrap\">",
"     percent/year),",
"    </span>",
"    while receiving glucocorticoids (7.5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent for &ge;3 months), who do not need estrogen replacement therapy because they have normal menstrual function. Bisphosphonates should be used with caution in premenopausal women given their long skeletal retention. There is insufficient information on the potential for harm to the fetus in women who become pregnant while currently or recently receiving bisphosphonates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Bisphosphonates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The therapeutic efficacy of bisphosphonates in patients with glucocorticoid-induced osteoporosis (GIO) has been thought to be related to their ability to promote osteoclast apoptosis (programmed cell death) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/24\">",
"     24",
"    </a>",
"    ]. However, glucocorticoids may negate the pro-apoptotic effect of bisphosphonates, suggesting that these drugs may prevent glucocorticoid-induced bone loss by prolonging the lifespan of osteoblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Alendronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    in patients receiving glucocorticoid therapy was demonstrated in a study of 477 patients age 17 to 83 years who were randomly assigned to receive one of two doses of alendronate or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/12\">",
"     12",
"    </a>",
"    ]. The mean bone mineral density of the lumbar spine increased by 2.1 and 2.9 percent over 48 weeks in the patients receiving 5 and 10 mg of alendronate daily, respectively, while decreasing 0.4 percent in the placebo group. Femoral neck, trochanter, and total body bone mineral density also increased significantly in the alendronate groups (",
"    <a class=\"graphic graphic_figure graphicRef52447 \" href=\"UTD.htm?31/38/32367\">",
"     figure 1",
"    </a>",
"    ). Those receiving alendronate had fewer new vertebral fractures compared with placebo (2.3 versus 3.7 percent), although fracture was not a primary outcome. These benefits were maintained for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/26\">",
"     26",
"    </a>",
"    ]. Once weekly alendronate (70 mg) similarly improves bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risedronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    is also effective for the prevention and treatment of osteoporosis, including glucocorticoid-induced osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/11,28,29\">",
"     11,28,29",
"    </a>",
"    ]. In a one-year randomized trial of risedronate versus placebo for the prevention of osteoporosis in 224 men and women who were beginning chronic glucocorticoid therapy, bone mineral density of the lumbar spine was unchanged in the risedronate treated groups, while it decreased by 2.8 percent in the placebo group (p&lt;0.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another one-year study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    versus placebo in 290 patients receiving glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &ge;7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for six or more months), lumbar spine and femoral neck bone mineral density increased by 2.7 and 1.8 percent, respectively, in the risedronate group, as compared with no change in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/28\">",
"     28",
"    </a>",
"    ]. The relative risk of vertebral fracture (a secondary outcome) was reduced by 70 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Zoledronic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    for the prevention and treatment of GIO was demonstrated in a one-year randomized trial of intravenous zoledronic acid (5 mg once) or daily oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    (5 mg) in 288 subjects who recently started glucocorticoids (prevention group) and 545 patients who had been taking them for more than three months (treatment group) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/30\">",
"     30",
"    </a>",
"    ]. In an analysis of subjects who received the study drug and had baseline and follow-up BMD measurements, zoledronic acid and risedronate increased mean BMD of the lumbar spine in both the prevention (2.6 and 0.6 percent, respectively) and treatment (4.1 and 2.7 percent, respectively) groups. The study was not designed to evaluate fractures, which occurred in three and five subjects in the risedronate and zoledronic acid groups, respectively.",
"   </p>",
"   <p>",
"    During the first three days, the occurrence of adverse events (predominantly arthralgias, fever, and flu-like symptoms) was greater in the ZA group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other bisphosphonates",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H622617\">",
"    <span class=\"h3\">",
"     Ibandronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data evaluating the efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    for the prevention and treatment of glucocorticoid-induced osteoporosis. However, intravenous ibandronate appears to preserve BMD. In an open label randomized trial of ibandronate (2 mg intravenously every three months for two years) versus alfacalcidiol (1 mcg daily) in 104 patients with established glucocorticoid-induced osteoporosis, IV ibandronate resulted in superior improvements in spine, femoral neck, and calcaneal BMD compared with alfacalcidiol (between group differences of 9.7, 3.4, and 7.9 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/31\">",
"     31",
"    </a>",
"    ]. These improvements were sustained in a third year of treatment, and there were fewer vertebral fractures (a secondary outcome) in the ibandronate group compared with the alfacalcidiol group (8.6 versus 22.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pamidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral and intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    have been shown to prevent glucocorticoid-induced bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/9,33-35\">",
"     9,33-35",
"    </a>",
"    ]. As an example, a randomized trial of intermittent intravenous pamidronate (30 mg every three months for one year) plus oral calcium versus oral calcium alone in patients starting long-term glucocorticoid therapy showed an increase in bone mineral density in both the spine and hip with pamidronate (2.3 and 2.6 percent, respectively), as compared with decreases of 4.6 and 2.2 percent, respectively, in the calcium-alone group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    is not available in the United States.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    has largely replaced IV pamidronate, which is now infrequently used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Etidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     Etidronate",
"    </a>",
"    , a less potent bisphosphonate than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    , prevents glucocorticoid-induced bone loss and reverses established osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/23,36-39\">",
"     23,36-39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    have largely replaced etidronate, which is now less frequently used in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Clodronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     Clodronate",
"    </a>",
"    , a bisphosphonate available in many countries but not available for use in the United States, increases bone density in glucocorticoid-treated patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bisphosphonates versus active D metabolites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superior efficacy of bisphosphonates compared with an active vitamin D metabolite among patients receiving glucocorticoid therapy has been demonstrated in several randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/17,18,31,32,41,42\">",
"     17,18,31,32,41,42",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 201 patients with rheumatic diseases who were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/14/37093?source=see_link\">",
"       alfacalcidol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      , 18 months of alendronate therapy was more effective in preventing bone loss at the lumbar spine, femoral neck, and total hip (absolute group differences of 4.0 percent [95% CI 2.4-5.5], 3.4 percent [95% CI 1.3-5.5], and 3.0 percent [95% CI 0.8-5.2], respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although not statistically significant, fewer patients administered alendronate had new vertebral fractures (three versus eight patients).",
"     </li>",
"     <li>",
"      In two studies of patients with glomerular disease (creatinine clearance &ge;30 or 70",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      (2.5 mg daily) was more effective than alfacalcidiol in preventing lumbar spine bone loss [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. The combination of risedronate and alfacalcidiol was similar to [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/42\">",
"       42",
"      </a>",
"      ] or better than [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/41\">",
"       41",
"      </a>",
"      ] risedronate monotherapy for preserving or improving bone density. However, the benefit of either therapy on fracture prevention in this patient population was not evaluated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H7#H7\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Use in chronic kidney disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PARATHYROID HORMONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroid PTH is generally not used as a first-line drug for treatment or prevention of glucocorticoid-induced osteoporosis because of its cost, subcutaneous route of administration, and the availability of other agents. However, we suggest parathyroid hormone (teriparatide) for the treatment of glucocorticoid-induced osteoporosis in men or postmenopausal women who:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have severe osteoporosis (T-score of -3.5 or below even in the absence of fractures; T-score of -2.5 or below plus a fragility fracture).",
"     </li>",
"     <li>",
"      Have osteoporosis (T-score below -2.5) who are unable to tolerate oral or intravenous bisphosphonates, or who have relative contraindications to bisphosphonates (achalasia, scleroderma esophagus, esophageal strictures).",
"     </li>",
"     <li>",
"      Fail other osteoporosis therapies (fracture with loss of BMD in spite of compliance with therapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Teriparatide is also an option for premenopausal women, as long as epiphyses are fully fused, who have fragility fractures or accelerated bone loss (&ge;4",
"    <span class=\"nowrap\">",
"     percent/year)",
"    </span>",
"    while receiving glucocorticoids (7.5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent for &ge;3 months), and who do not need estrogen replacement therapy because they have normal menstrual function.",
"   </p>",
"   <p>",
"    Teriparatide is not recommended for more than two years based upon the potential risk of carcinogenicity. Treatment with an antiresorptive agent (eg, bisphosphonates) after PTH preserves the gains in BMD achieved with PTH. Thus, for patients who receive teriparatide as initial treatment and who remain at high risk for fracture after discontinuation, a bisphosphonate should be started after PTH is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=see_link&amp;anchor=H22#H22\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'After PTH'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Parathyroid hormone (PTH) stimulates bone formation as well as resorption, and intermittent administration stimulates formation more than resorption. Initial studies show that it is beneficial in patients with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .) Because the predominant effect of glucocorticoids on the skeleton is to reduce bone formation, and bisphosphonates (antiresorptive agents) do not address this mechanism of bone loss, treatment with parathyroid hormone is theoretically a more appealing approach [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized trials, PTH is effective in improving BMD in patients treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/20,44-46\">",
"     20,44-46",
"    </a>",
"    ]. As an example, in an 18-month randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (10 mg orally daily) versus PTH 1-34 (teriparatide, 20 mcg subcutaneously daily) in 428 men and women who had taken glucocorticoids for &ge;3 months (&ge;5 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent daily), both treatments significantly increased BMD. However, teriparatide was associated with a greater increase in lumbar spine (8.2 versus 3.9 percent), total hip (3.8 versus 2.4 percent), and femoral neck (4.4 versus 2.8 percent) BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    There was no difference in the incidence of nonvertebral fractures, a secondary outcome (5.6 versus 3.7 percent), but there were fewer new radiographic vertebral fractures (1 versus 10) in subjects randomly assigned to teriparatide compared with alendronate. Thirty percent of subjects in each treatment group discontinued the study prior to completion. There was more nausea and insomnia in the teriparatide group and more rashes in the alendronate group.",
"   </p>",
"   <p>",
"    In a secondary analysis by gender and menopausal status, the increase in lumbar spine BMD was significantly greater in the teriparatide group for both premenopausal (7.0 versus 0.7 percent) and postmenopausal (7.8 versus 3.7 percent) women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/22\">",
"     22",
"    </a>",
"    ]. In premenopausal women, fractures were infrequent in both treatment groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    The trial was designed to have an 18 month continuation phase, with prespecified secondary outcomes that included BMD, fractures, and adverse events at 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/44\">",
"     44",
"    </a>",
"    ]. After 36 months (n = 241 subjects), increases in BMD from baseline remained significantly greater in the teriparatide group (11 versus 5.3, 5.2 versus 2.7, and 6.3 versus 3.4 percent for lumbar spine, total hip, and femoral neck, respectively). New vertebral fractures occurred significantly less often in patients receiving teriparatide (3 versus 13 in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    group). The majority of vertebral fractures occurred in the first 18 months. There was no difference in the incidence of nonvertebral fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HORMONE REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For premenopausal women of childbearing potential taking or initiating glucocorticoids who are hypogonadal, we suggest",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    replacement (eg, oral contraceptives). For men with symptomatic glucocorticoid-induced hypogonadism, we suggest testosterone replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Estrogen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids reduce the production of sex steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/47\">",
"     47",
"    </a>",
"    ]. As a result, it is logical to replace these hormones if the patient is deficient, as suggested by symptoms such as amenorrhea in premenopausal women or decreased libido in men and confirmed by finding low estradiol or testosterone, respectively. In a cross-sectional study of 119 perimenopausal women with asthma (65 receiving oral glucocorticoids), the asthmatic women who were not taking hormone replacement therapy had lower mean BMD than did nonasthmatics [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/48\">",
"     48",
"    </a>",
"    ]. This observation plus the extensive literature supporting the value of estrogen in the prevention of postmenopausal osteoporosis makes it likely that estrogen therapy can help reduce or reverse bone loss in hypoestrogenic women treated with glucocorticoids.",
"    <span class=\"nowrap\">",
"     Estrogen/progestin",
"    </span>",
"    treatment should be prescribed (if not contraindicated) for premenopausal women who are hypogonadal while taking glucocorticoids. There is no reason to believe, however, that treatment with estrogens will benefit young women with normal ovarian function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link&amp;anchor=H3033285#H3033285\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials in postmenopausal women have shown that long-term use of combined oral estrogen-progestin therapy does not reduce the risk of coronary heart disease as was expected based on observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, combination therapy increased the risk of breast cancer, stroke, and venous thromboembolism. Thus, estrogen is no longer considered a first-line drug for prevention of postmenopausal osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A crossover study of 15 men with glucocorticoid-dependent asthma and low baseline serum testosterone concentrations found that monthly intramuscular administration of 250 mg testosterone reversed the deleterious effect of glucocorticoids on bone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/50\">",
"     50",
"    </a>",
"    ]. Bone density in the lumbar spine increased 5.0 percent during testosterone therapy, compared with no change during the control period. In addition, a randomized, placebo-controlled trial of testosterone in unselected men taking glucocorticoids described an increase in spine bone mineral density, fat mass, and muscle strength in the testosterone versus placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/51\">",
"     51",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    We favor bisphosphonates for prevention and treatment of glucocorticoid-induced osteoporosis in men because they are known to reduce fracture risk. Such men who develop symptomatic hypogonadism, however, should also be treated with testosterone for its benefits on muscle, energy, and libido, as well as on bone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of osteoporosis in men\", section on 'Testosterone therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H16#H16\">",
"     \"Testosterone treatment of male hypogonadism\", section on 'Bone density'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Calcitonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar spine bone loss is also attenuated with subcutaneous or intranasal calcitonin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. However, calcitonin has not been found to reduce the risk of fractures in glucocorticoid-treated patients. A meta-analysis of nine trials comparing calcitonin to placebo for the treatment of these patients reported no efficacy of calcitonin on femoral neck BMD or on vertebral or nonvertebral fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/54\">",
"     54",
"    </a>",
"    ]. Thus, calcitonin is not considered first line therapy for the treatment or prevention of glucocorticoid-induced osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/45\">",
"     45",
"    </a>",
"    ]. Calcitonin could be considered, however, in patients who cannot tolerate oral or intravenous bisphosphonates or teriparatide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=see_link\">",
"     \"Calcitonin in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30031287\">",
"    <span class=\"h2\">",
"     Denosumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a monoclonal antibody to an osteoclast differentiating factor. It inhibits osteoclast formation, decreases bone resorption, increases BMD, and reduces the risk of fracture. It has been used in postmenopausal women and in men undergoing androgen deprivation therapy for prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=see_link\">",
"     \"Denosumab for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a mouse model of glucocorticoid-induced osteoporosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    compared with placebo prevented bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/55\">",
"     55",
"    </a>",
"    ]. In a post-hoc analysis of BMD results from a randomized trial of denosumab versus placebo in patients with rheumatoid arthritis (some receiving glucocorticoids), denosumab significantly increased mean lumbar spine and total hip BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/56\">",
"     56",
"    </a>",
"    ]. Until additional data are available, we do not recommend denosumab for the prevention or treatment of glucocorticoid-induced osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Effect of cessation of glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be a significant increase in bone density after discontinuation of exogenous glucocorticoid therapy or reversal of endogenous Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. One study, as an example, examined spine bone mineral density after successful treatment for Cushing's disease in 20 patients, all of whom had marked osteoporosis of lumbar spine and femoral neck [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/57\">",
"     57",
"    </a>",
"    ]. There was no change in bone mineral density for six months, the time required for gradual reversal of increased osteoclastic activity, after which bone mineral density increased. However, patients who have had a fracture may have permanent deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2707796\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pharmacologic therapy for men and postmenopausal women, we favor bisphosphonates as first-line therapy. We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    because of clinical trial data demonstrating efficacy in men and women with glucocorticoid-induced osteoporosis. For such patients who cannot tolerate oral bisphosphonates or who have difficulty with the dosing requirements, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    is an acceptable alternative. We typically reserve parathyroid hormone (teriparatide) for patients with severe osteoporosis (T-score of -3.5 or below even in the absence of fractures or a T-score of -2.5 or below plus a fragility fracture). In addition, teriparatide is an option for patients who are unable to tolerate any of the available bisphosphonates or who continue to fracture after one year of bisphosphonate therapy.",
"   </p>",
"   <p>",
"    For premenopausal women with fractures or accelerated bone loss who do not need estrogen replacement therapy because they have normal ovarian function, bisphosphonates are generally the drugs of choice. Teriparatide is an alternative option for such women, as long as epiphyses are fully fused. Potential short- and long-term risks, as well as potential effects on the fetus, should be considered as part of the decision to use bisphosphonates or teriparatide for the treatment of premenopausal osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2707788\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several published guidelines for monitoring the response to osteoporosis therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"    </a>",
"    .) Although all recommend follow-up BMD testing, there is no consensus on the optimal frequency of monitoring and the preferred site to monitor. We typically measure BMD (dual energy x-ray absorptiometry) of the lumbar spine and hip at the initiation of glucocorticoid therapy and after one year. If BMD is stable or improved, we measure it less frequently (every two to three years) thereafter. If glucocorticoids are discontinued and BMD is stable, measurement at five year intervals may be sufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Rheumatology (ACR) guidelines recommend intervention based upon risk of fracture (high, medium, low), guided in part by the World Health Organization Fracture Risk Assessment Tool (",
"    <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"     FRAX",
"    </a>",
"    ) or by ACR-provided examples of low, medium, and high risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/3,59\">",
"     3,59",
"    </a>",
"    ]. Low risk is defined by a 10-year risk of a major osteoporotic fracture of 10 percent or less, medium risk 10 to 20 percent, and high risk &gt;20 percent or a T-score below -2.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/3\">",
"     3",
"    </a>",
"    ]. FRAX is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link&amp;anchor=H4#H4\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Fracture risk assessment tool'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of osteoporosis in men\", section on 'Candidates for therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to calcium and vitamin D supplementation, bisphosphonate therapy is recommended for prevention of bone loss and fractures in postmenopausal women and men &ge;50 years receiving or initiating glucocorticoids with an anticipated duration of &ge;3 months.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For low-risk patients, bisphosphonates (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      ) are recommended if the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose is &ge;7.5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      For medium risk patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      is recommended for any dose of glucocorticoids, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      is an option for patients receiving &ge;7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For high risk patients, bisphosphonates are recommended for any dose and duration of glucocorticoids. Teriparatide is an option for high risk patients taking &ge;5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      with anticipated duration of &le;1 month and for any dose of glucocorticoids with a duration of &gt;1 month [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For at risk (previous fragility fracture) men &lt;50 years and premenopausal women who do not have childbearing potential, bisphosphonates (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      ) are recommended for those taking &ge;5 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily for more than one month.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       Zoledronic acid",
"      </a>",
"      is an option for patients receiving prednisone &ge;7.5 mg daily, and zoledronic acid and teriparatide are options for patients receiving glucocorticoids for more than three months.",
"     </li>",
"     <li>",
"      The ACR provides separate therapeutic guidelines for premenopausal women of childbearing potential [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/3\">",
"       3",
"      </a>",
"      ]. For high risk premenopausal women (eg, previous fragility fracture), bisphosphonates are recommended only for those women taking &ge;7.5 mg daily of glucocorticoids for more than three months. Teriparatide is an alternative option for such women. For women taking &lt;7.5 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily or taking glucocorticoids for one to three months, the ACR panel could not reach a consensus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient should be followed yearly to determine if bone loss continues. An exercise program should also be initiated, although this may be limited by restrictions from the underlying illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other published guidelines largely agree with the recommendations above, except for some minor differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Belgian Bone Club recommends consideration of prevention or treatment in any adult taking a daily dose of at least 7.5 mg equivalent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      daily for &ge;3 months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/60\">",
"       60",
"      </a>",
"      ]. Calcium (500 to 1000 mg daily) and vitamin D (800 to 1000 IU daily) are recommended, in addition to bisphosphonates (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      ). Treatment is continued until steroids are tapered.",
"     </li>",
"     <li>",
"      The Royal College of Physicians recommends beginning antiresorptive therapy at the time of starting glucocorticoids in patients at high risk for fracture (eg, &ge;65 years of age, history of prior fragility fracture) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/36/17994/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"       \"Osteoporotic fracture risk assessment\"",
"      </a>",
"      .) Bone density testing should be considered in other individuals who will be receiving glucocorticoids for &ge;3 months, and therapy considered for those with a T-score of &le;-1.5 or with a reduction of BMD &gt;4 percent after one year. Good nutrition, adequate dietary calcium intake, and a bisphosphonate are recommended as therapy.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       Alendronate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"       etidronate",
"      </a>",
"      are its preferred bisphosphonates because a reduction in vertebral fracture has been noted in secondary analyses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;What follows are the broad guidelines that we use to minimize glucocorticoid-induced bone loss in individuals initiating or receiving glucocorticoids daily. However, therapy must be adjusted according to the unique circumstances of each patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623471\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid dose and the duration of therapy should be as low and as short as possible, because even replacement doses can cause bone loss. Patients should be encouraged to do weight-bearing exercises for protection against both bone loss and muscle atrophy. Patients should avoid smoking and excess alcohol and take measures to prevent falls. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients receiving any dose of chronic glucocorticoid therapy or initiating glucocorticoids with an anticipated duration of &ge;3 months, we recommend calcium and vitamin D supplementation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Most individuals require 1200 mg of elemental calcium daily, total diet plus supplement, and 800 IU of vitamin D daily. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Calcium and vitamin D'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623509\">",
"    <span class=\"h2\">",
"     Candidates for pharmacologic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men &ge;50 years and postmenopausal women with established osteoporosis (T-score &le;-2.5 or fragility fracture) who are receiving or are about to initiate glucocorticoids (any dose for any duration), we recommend pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H622960\">",
"       'Established osteoporosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of high risk men &ge;50 years and postmenopausal women (who are initiating or are treated with any dose of glucocorticoids for any duration) who have T-scores between -1.0 and -2.5, we suggest pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A reasonable cut point to indicate high risk that may be cost-effective in some settings is a FRAX calculated 10-year probability of hip or combined major osteoporotic fracture of &ge;3 or 20 percent, respectively. For postmenopausal women and men &gt;50 years who have a FRAX calculated absolute risk below these cut points, we suggest pharmacologic therapy if they are taking &ge;7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or its equivalent for an anticipated duration of &ge;3 months (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H622982\">",
"       'Osteoporosis prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For premenopausal women who do not need estrogen replacement therapy because they have normal ovarian function, who have a fragility fracture while receiving glucocorticoids (7.5 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      equivalent for &ge;3 months), and who do not have contraindications to bisphosphonates or teriparatide, we recommend pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For similar women who do not have a fragility fracture but have accelerated bone loss (&ge;4",
"      <span class=\"nowrap\">",
"       percent/year)",
"      </span>",
"      while receiving glucocorticoids, we also suggest pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H622811\">",
"       'Premenopausal women and younger men'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men &lt;50 years of age who have a fragility fracture while receiving glucocorticoids (7.5 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      equivalent for &ge;3 months),",
"      <strong>",
"      </strong>",
"      we recommend pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For similar men who do not have a fragility fracture but have accelerated bone loss (&ge;4",
"      <span class=\"nowrap\">",
"       percent/year),",
"      </span>",
"      we also suggest pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H622811\">",
"       'Premenopausal women and younger men'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623546\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men and postmenopausal women, we suggest bisphosphonates as first line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) . We prefer weekly oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      over other oral bisphosphonates because of clinical trial data demonstrating efficacy in women and men with glucocorticoid-induced osteoporosis. Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      is an option for patients unable to tolerate oral bisphosphonates or who have difficulty with the dosing requirements. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bisphosphonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parathyroid hormone is generally not used as a first-line drug for treatment or prevention of glucocorticoid-induced osteoporosis because of its cost, subcutaneous route of administration, and the availability of other agents. However, for the prevention or treatment of glucocorticoid-induced osteoporosis in men or postmenopausal women with osteoporosis (T-score below -2.5) who are unable to tolerate any of the available bisphosphonates, we suggest parathyroid hormone (teriparatide) over other available therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Other candidates for parathyroid hormone include patients with severe osteoporosis (T-score of -3.5 or below even in the absence of fractures or a T-score of -2.5 or below plus a fragility fracture) and patients who fail other osteoporosis therapies (fracture with loss of BMD in spite of compliance with therapy). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Parathyroid hormone'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=see_link&amp;anchor=H41#H41\">",
"       \"Parathyroid hormone therapy for osteoporosis\", section on 'Candidates'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For premenopausal women of childbearing potential taking or initiating glucocorticoids, who are hypogonadal, we suggest",
"      <span class=\"nowrap\">",
"       estrogen/progestin",
"      </span>",
"      replacement if not contraindicated (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hormone replacement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H10#H10\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Estrogen'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link&amp;anchor=H3033285#H3033285\">",
"       \"Overview of the use of estrogen-progestin contraceptives\", section on 'Contraindications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For premenopausal women of childbearing potential taking or initiating glucocorticoids (7.5 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      equivalent for &ge;3 months), who do not need estrogen replacement therapy because they have normal menstrual function, and who have a fragility fracture or accelerated bone loss (&ge;4",
"      <span class=\"nowrap\">",
"       percent/year),",
"      </span>",
"      we suggest bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Teriparatide is an alternative option for such women, as long as epiphyses are fully fused. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bisphosphonates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Parathyroid hormone'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We recommend caution when considering bisphosphonates or teriparatide in premenopausal women. It is important to consider the potential for harm to the fetus in women who become pregnant and are currently receiving teriparatide or who are currently receiving or were recently treated with bisphosphonates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link&amp;anchor=H9#H9\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Pharmacologic therapies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=see_link&amp;anchor=H37#H37\">",
"       \"Parathyroid hormone therapy for osteoporosis\", section on 'Premenopausal women'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Although estrogen replacement therapy prevents bone loss in postmenopausal women receiving glucocorticoid therapy, estrogen-progestin therapy is no longer a first-line approach for the prevention or treatment of osteoporosis in postmenopausal women because of increased risk of breast cancer, stroke, venous thromboembolism, and coronary disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"       \"Postmenopausal hormone therapy: Benefits and risks\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For symptomatic hypogonadal men who do not have contraindications to testosterone therapy, we recommend replacement of testosterone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For asymptomatic hypogonadal men taking high-dose glucocorticoids, testosterone can also be considered for its potential benefits on muscle, energy, and libido. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Hormone replacement'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=see_link&amp;anchor=H2#H2\">",
"       \"Testosterone treatment of male hypogonadism\", section on 'General principles'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626125\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically measure bone mineral density (BMD) at the initiation of glucocorticoid therapy and after one year. If BMD is stable or improved, we measure BMD less frequently (every two to three years) thereafter. (See",
"    <a class=\"local\" href=\"#H2707788\">",
"     'Monitoring'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/1\">",
"      van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/2\">",
"      Heffernan MP, Saag KG, Robinson JK, Callen JP. Prevention of osteoporosis associated with chronic glucocorticoid therapy. JAMA 2006; 295:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/3\">",
"      Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/4\">",
"      Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994; 120:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/5\">",
"      Reid DM, Nicoll JJ, Smith MA, et al. Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica. Br Med J (Clin Res Ed) 1986; 293:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/6\">",
"      Wang WQ, Ip MS, Tsang KW, Lam KS. Antiresorptive therapy in asthmatic patients receiving high-dose inhaled steroids: a prospective study for 18 months. J Allergy Clin Immunol 1998; 101:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/7\">",
"      Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; :CD000952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/8\">",
"      Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/9\">",
"      Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001; 16:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/10\">",
"      Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/11\">",
"      Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/12\">",
"      Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/13\">",
"      Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001; 44:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/14\">",
"      Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/15\">",
"      Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/16\">",
"      Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/17\">",
"      Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/18\">",
"      de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006; 355:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/19\">",
"      Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000; :CD001347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/20\">",
"      Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/21\">",
"      MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/22\">",
"      Langdahl BL, Marin F, Shane E, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 2009; 20:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/23\">",
"      Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/24\">",
"      Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/25\">",
"      Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002; 109:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/26\">",
"      Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/27\">",
"      Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009; 36:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/28\">",
"      Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/29\">",
"      Eastell R, Devogelaer JP, Peel NF, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/30\">",
"      Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/31\">",
"      Ringe JD, Dorst A, Faber H, et al. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford) 2003; 42:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/32\">",
"      Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003; 14:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/33\">",
"      Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988; 1:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/34\">",
"      Reid IR, Heap SW, King AR, Ibbertson HK. Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet 1988; 2:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/35\">",
"      Gallacher SJ, Fenner JA, Anderson K, et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992; 47:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/36\">",
"      Wolfhagen FH, van Buuren HR, den Ouden JW, et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997; 26:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/37\">",
"      Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995; 99:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/38\">",
"      Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998; 83:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/39\">",
"      Pitt P, Li F, Todd P, et al. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax 1998; 53:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/40\">",
"      Herrala J, Puolijoki H, Liippo K, et al. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone 1998; 22:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/41\">",
"      Kikuchi Y, Imakiire T, Yamada M, et al. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. Nephrol Dial Transplant 2007; 22:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/42\">",
"      Fujii N, Hamano T, Mikami S, et al. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant 2007; 22:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/43\">",
"      Carpinteri R, Porcelli T, Mejia C, et al. Glucocorticoid-induced osteoporosis and parathyroid hormone. J Endocrinol Invest 2010; 33:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/44\">",
"      Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60:3346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/45\">",
"      Lane, NE, Sanchez, S, Modin, GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/46\">",
"      Gl&uuml;er CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/47\">",
"      MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/48\">",
"      Laatikainen AK, Kr&ouml;ger HP, Tukiainen HO, et al. Bone mineral density in perimenopausal women with asthma: a population-based cross-sectional study. Am J Respir Crit Care Med 1999; 159:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/49\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/50\">",
"      Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/51\">",
"      Crawford BA, Liu PY, Kean MT, et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88:3167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/52\">",
"      Luengo M, Pons F, Martinez de Osaba MJ, Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994; 49:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/53\">",
"      Montemurro L, Schiraldi G, Fraioli P, et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991; 49:71.",
"     </a>",
"    </li>",
"    <li>",
"     Cranney, A, Welch, V, Adachi, J, et al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews 2000; CD001983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/55\">",
"      Hofbauer LC, Zeitz U, Schoppet M, et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 2009; 60:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/56\">",
"      Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010; 69:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/57\">",
"      Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995; 80:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/58\">",
"      Pocock NA, Eisman JA, Dunstan CR, et al. Recovery from steroid-induced osteoporosis. Ann Intern Med 1987; 107:319.",
"     </a>",
"    </li>",
"    <li>",
"     file://mail3.rheumatology.org/practice/clinical/guidelines/ACR_2010_GIOP_Recomm_Clinicians_Guide.pdf (Accessed on January 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/36/17994/abstract/60\">",
"      Devogelaer JP, Goemaere S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006; 17:8.",
"     </a>",
"    </li>",
"    <li>",
"     www.rcplondon.ac.uk/pubs/books/glucocorticoid (Accessed on January 17, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2034 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17994=[""].join("\n");
var outline_f17_36_17994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CALCIUM AND VITAMIN D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Active vitamin D metabolites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H622797\">",
"      CANDIDATES FOR PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H622960\">",
"      Established osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H622982\">",
"      Osteoporosis prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H622811\">",
"      Premenopausal women and younger men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BISPHOSPHONATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Alendronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risedronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Zoledronic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H622617\">",
"      - Ibandronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pamidronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Etidronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Clodronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bisphosphonates versus active D metabolites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PARATHYROID HORMONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HORMONE REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Calcitonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30031287\">",
"      Denosumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Effect of cessation of glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2707796\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2707788\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H623471\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H623509\">",
"      Candidates for pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H623546\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626125\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2034|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/38/32367\" title=\"figure 1\">",
"      Alendronate steroid BMD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=related_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_36_17995="Emergency pericardiocentesis equipment";
var content_f17_36_17995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Equipment for emergency pericardiocentesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Sterile gown, gloves, and mask",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile barrier drapes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorhexidine-based skin preparation solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 to 25-gauge needle for local anesthetic infiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringes (10 and 60 mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Three-way stopcock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plastic drainage tubing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18-gauge 7 cm large bore introducer needle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexible or curved-tip (J) guidewire",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         6 to 8 French drainage catheter (pigtail, sheath, or central venous catheter)",
"        </p>",
"        <p>",
"         (Supplies in a standard 7 French central venous catheter set are good immediate substitutes)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echocardiographic system with 2-5 MHz transducer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasound needle guide",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The list above includes all equipment that may be necessary to perform emergency pericardiocentesis. Time to obtain all materials may not be available in life-threatening circumstances.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17995=[""].join("\n");
var outline_f17_36_17995=null;
var title_f17_36_17996="Prob 10 year survival white men older than 70 RP prostate cancer";
var content_f17_36_17996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Probability (95% confidence interval) of 10-year overall survival in white men &ge;70 years old undergoing radical prostatectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Gleason 6",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Gleason 7",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Gleason 8-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Charlson comorbidity index",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Charlson comorbidity index",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Charlson comorbidity index",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         PSA",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &gt;1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &gt;1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &gt;1",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         0-9.9",
"        </strong>",
"       </td>",
"       <td>",
"        85 (80-90)",
"       </td>",
"       <td>",
"        64 (53-76)",
"       </td>",
"       <td>",
"        81 (75-86)",
"       </td>",
"       <td>",
"        57 (46-69)",
"       </td>",
"       <td>",
"        76 (69-84)",
"       </td>",
"       <td>",
"        48 (36-65)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         10-19.9",
"        </strong>",
"       </td>",
"       <td>",
"        76 (68-84)",
"       </td>",
"       <td>",
"        47 (35-65)",
"       </td>",
"       <td>",
"        70 (62-79)",
"       </td>",
"       <td>",
"        39 (27-55)",
"       </td>",
"       <td>",
"        64 (54-75)",
"       </td>",
"       <td>",
"        30 (18-49)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         &ge;20",
"        </strong>",
"       </td>",
"       <td>",
"        72 (63-82)",
"       </td>",
"       <td>",
"        41 (28-62)",
"       </td>",
"       <td>",
"        66 (57-76)",
"       </td>",
"       <td>",
"        32 (21-50)",
"       </td>",
"       <td>",
"        59 (48-71)",
"       </td>",
"       <td>",
"        24 (14-42)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Tewari, A, Johnson, CC, Divine, G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171:1513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17996=[""].join("\n");
var outline_f17_36_17996=null;
var title_f17_36_17997="Lead time bias";
var content_f17_36_17997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    How lead time affects survival time after screening",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 230px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shaded areas indicate length of survival after diagnosis (Dx).",
"    <div class=\"footnotes\">",
"     O: onset of disease.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Fletcher, RF, Fletcher, SW. Prevention. In: Clinical Epidemiology: The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17997=[""].join("\n");
var outline_f17_36_17997=null;
var title_f17_36_17998="Tzanck prep skin lesion";
var content_f17_36_17998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tzanck prep skin lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17998=[""].join("\n");
var outline_f17_36_17998=null;
var title_f17_36_17999="Glioblastoma nomogram for survival prediction";
var content_f17_36_17999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78955&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Nomogram for predicting median survival and probability of survival at 2 years in all randomised patients (population 1)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gorlia, T, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology 2007; 9:29. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_36_17999=[""].join("\n");
var outline_f17_36_17999=null;
